Tirzepatide Provider Comparison
Comparison matrix
Prices 35 verified of 86 Rubric v1.0-draft Prices verified 0 of 86 Evidence records 90 verified Corrections open log

Research

Tirzepatide Research and Clinical Studies

Trial pages that keep the result attached to its population, dose, comparator and timeframe — because separating them is how a trial becomes a marketing claim.

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published Updated Sources captured Medically reviewed not yet — why

Direct answer

Each trial page records design, population, sample size, intervention and dose, comparator, duration, primary endpoint, result, adverse events and limitations together, with registry and publication identifiers. Sources are the registry entry and the peer-reviewed paper, never a press release or a secondary article.

Answer last reviewed: not yet reviewed
Trial capture status
Captured from primary sources — 12 (67%)Not yet captured — 6 (33%)18records
Show this figure as a table
Data table
StatusRecordsShare
Captured from primary sources1267%
Not yet captured633%
Captured means the registry entry and the peer-reviewed publication have both been read.
What every trial page must state together
What every trial page must state together
ElementWhy it cannot be separated from the result
PopulationA result in trial participants may not transfer to you
DoseResults at 15 mg are not results at a microdose
ComparatorBeating placebo is not beating another drug
DurationA 72-week figure is not a 12-week expectation
DiscontinuationsEfficacy in completers overstates real-world effect
LimitationsFunding, blinding and dropout handling change interpretation
A percentage quoted without these six is a marketing line, whoever is quoting it.

How to read a trial page here

Every trial record carries the same fields in the same order: design, population, sample size, intervention, dose, comparator, duration, primary endpoint, result, adverse events, discontinuations and limitations — with the registry identifier and publication reference where we hold them.

Where a field is blank, we have not captured it. Blank fields stay visible rather than being dropped, so the gaps are countable.

The two things we check that most summaries do not

Which estimand produced the figure. Trials frequently publish more than one analysis. SURMOUNT-1 reported 15.0%, 19.5% and 20.9% on the treatment-regimen analysis and 16.0%, 21.4% and 22.5% on the efficacy analysis. Marketing generally quotes the higher set without saying which. We name it.

Whether the result transfers. Every efficacy figure in this field comes from a trial of an FDA-approved product at a studied dose. It does not transfer to a compounded preparation, a microdose, or an orally disintegrating tablet — and those figures are quoted for exactly those products constantly.

What we will not publish

A trial figure we cannot trace to a peer-reviewed publication or a registry results posting. That standard costs us search position on the highest-demand queries in this category, and abandoning it would undermine every other claim on the site.

Cite this pageCC BY 4.0

Tirzepatide Provider Comparison. “Tirzepatide Research and Clinical Studies.” S.J Partners LLC, 2026-07-26. https://tirzepatideprovidercomparison.com/research/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4